Partial pressure

Gut microbiome: meet Bilophila wadsworthia – a microbe that’s both friend and foe

Retrieved on: 
Friday, February 16, 2024
Hydrogen, Oxygen, Fungus, Smell, Partial pressure, Diet, Inflammation, News, Growth, Bile, Hydrogen sulfide, Meat, Cell, Defecation, Health, Irritable bowel syndrome, Bacteria, Virus, Appendicitis, Inflammatory bowel disease, Disease, Archaea, Fermentation, Colorectal cancer, Research, Sulfur

Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.

Key Points: 
  • Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.
  • Bilophila wadsworthia is one such species of these bacteria.
  • The bacteria that break down sulfur-containing organic matter and produce hydrogen sulfide are fittingly called sulfate-reducing bacteria.
  • Sulfate-reducing bacteria are an important part of the normal human gut microbiome, and small amounts of hydrogen sulfide are required in the human gut environment.
  • Bilophila wadsworthia was discovered in the 1980s, when it was found in people who had severe appendicitis.
  • The researchers found that it grew really well in bile, which is why the genus name is Bilophila (meaning bile loving).
  • Since then, research has associated Bilophila wadsworthia with negative effects in the gut.
  • It’s not clear how or why expansion of Bilophila wadsworthia can occur in the gut.


Jade Davies receives funding from UKRI via the BBSRC as part of the Norwich Research Park Doctoral Training Partnership (grant no. BB/M011216/1).

LI-COR Environmental Purchases Apollo SciTech Assets

Retrieved on: 
Wednesday, November 1, 2023
PH, PCO2, Apollo, Carbon, Atmosphere, Biophysical environment, LI-COR, LINCOLN, Research, Battery Ventures, CO2, Partial pressure, Ocean, DIC, Climate change, Agriculture, Talk

LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.

Key Points: 
  • LI-COR, a leader in environmental measurement technology, extends its reach to the oceans with the purchase of Apollo SciTech assets.
  • LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.
  • Apollo SciTech instruments are used worldwide.
  • Two of Apollo SciTech's top-selling assets—the dissolved inorganic carbon (DIC) analyzers and the partial pressure of CO2 (pCO2) models—currently incorporate LI-COR technology.

LI-COR Environmental Purchases Apollo SciTech Assets

Retrieved on: 
Wednesday, November 1, 2023
PH, PCO2, Apollo, Carbon, Atmosphere, Biophysical environment, LI-COR, LINCOLN, Research, Battery Ventures, CO2, Partial pressure, Ocean, DIC, Climate change, Fossil fuel, Talk

LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.

Key Points: 
  • LI-COR, a leader in environmental measurement technology, extends its reach to the oceans with the purchase of Apollo SciTech assets.
  • LINCOLN, Neb., Nov. 1, 2023 /PRNewswire/ -- LI-COR Environmental, a leader in greenhouse gas measurement technology, purchased the assets of Apollo SciTech LLC, a Delaware company that makes instrumentation for aquatic carbon dioxide parameter analysis.
  • LI-COR, a leader in greenhouse gas measurement technology, extends to the oceans with purchase of Apollo SciTech assets.
  • Apollo SciTech, founded in 2001, produces high-quality instruments that use carbon dioxide parameters (DIC, TAlk, pH, and pCO2) as measures of biological activity in aquatic environments.

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Retrieved on: 
Wednesday, August 30, 2023
Cardiology, Software, Health, FDA, Medical Devices, Health Technology, Technology, Other Health, Partnership, PLC, ILBM, LIVN, Perfusion, Hematocrit, Oxygen, CE marking, Food and Drug Administration, LivaNova, CPB, Multimedia, Temperature, Cardiopulmonary bypass, Sale, United Arab Emirates, CLIA, Journal, Acute kidney injury, GDP, Patient, Risk, Stazione Sperimentale per le Industrie delle Essenze e dei Derivati dagli Agrumi, Clinical Laboratory Improvement Amendments, Perfusionist, HLM, Partial pressure, Food, Monitoring (medicine), Medical device, Medical imaging

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.
  • “Dynamic conditions can rapidly change a patient’s blood parameters during a cardiopulmonary bypass procedure,” said Marco Dolci, LivaNova President, Cardiopulmonary.
  • “The Essenz In-Line Blood Monitor provides continuous monitoring throughout a patient’s procedure.
  • It consists of a next-generation heart-lung machine (HLM), a patient monitor and accurate sensing technology that now includes the ILBM.

Global Traumatic Brain Injuries Assessment Market Expected to Garner $18,373.6 Million by 2031, Growing at 7.0% CAGR from 2022-2031 [250-Pages] | Details by Research Dive

Retrieved on: 
Tuesday, January 17, 2023
Accident, Blunt trauma, Hospital, Falls, Brain, Injury, Research, Brain damage, CT, Partial pressure, Completeness, Midsayap Diagnostic Center and Hospital, Growth, Patient, Intracranial pressure monitoring, Coronavirus, Partial, Traumatic brain injury, MRI, Cranial cavity, Others, Meat, Medical imaging, Medical device, Oxygen, Electronics

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Traumatic Brain Injuries Assessment Market, by End-user (Hospital, Diagnostics Center, and Others) and Diagnostic Type (CT-Scan, MRI, Electronics, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue (pBrO2), and Others) Global Opportunity Analysis and Industry Forecast, 2022-2031".

Key Points: 
  • The traumatic brain injuries assessment market is expected to grow by 2031 due to increasing cases of brain injuries.
  • This global increase is expected to immensely help the traumatic brain injuries assessment market grow in the forecast years.
  • Restraints: Low government funding in traumatic brain injury treatment, however, may dampen the growth rate of the traumatic brain injuries assessment market.
  • By regional analysis, the traumatic brain injuries assessment market in North America region is expected to be the most dominant by 2031.

New Study from StrategyR Highlights a $4.9 Billion Global Market for Carbon Capture and Storage by 2026

Retrieved on: 
Tuesday, March 1, 2022
Carbon, Chevron Corporation, Carbon capture and storage, Hydrogen, Carbonate, Growth, CO2, Industrial separation processes, EOR, Polyurethane, Internet, Intelligence, COVID-19, Schlumberger, Players, Revolution, HTC, SAN, Biofuel, Partial pressure, Adiabatic flame temperature, Forecasting, Enhanced oil recovery, Food, GIA, Attention, Power, GE Power, Biomass, ADM (company), Technology, Marketing, Equinor, Post-combustion capture, CCS, CAGR, BP, Research, Time, Policy, Renewable energy, Coal, Others

SAN FRANCISCO, March 1, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Carbon Capture and Storage - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 1, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Carbon Capture and Storage - Global Market Trajectory & Analytics" .
  • Carbon capture efforts are further favored by increasing focus of companies to investigate new use cases for captured carbon dioxide.
  • This segment currently accounts for a 11.3% share of the global Carbon Capture and Storage market.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Endpoint Health Presents Published Results from a Retrospective Study of Adult ARDS Patients, Identifying an Innovative Approach to Predicting Clinical Outcomes

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, Health, Clinical Trials, Other Health, OH, Blood gas tension, Blood, Genetically modified bacteria, Safety, Rajneesh Duggal, Oxygen, Health, Fraction of inspired oxygen, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Respiratory rate, Doctor of Philosophy, Â, Therapy, Review, Inhalation, Research, Injury, Patient, Adult, Bilirubin, Ventilation, Cleveland Clinic, BMJ, BMJ Open, Acute pancreatitis, Sepsis, Social, Partial pressure, Twitter, American Thoracic Society, Disease, MD, Department, Cleveland, Creatinine, Inflammation, Mortality, Rheumatoid arthritis, Endpoint, Heart rate, Chest injury, Social media, Pneumonia, Survivor, Critical Care Medicine (journal), Acute respiratory distress syndrome, Pharmaceutical industry, Medical imaging, Medical device, Dietary supplement, the Study, ARDS, Endpoint Health, THE STUDY, ARDS, ENDPOINT HEALTH

The clinical utility of subphenotypic assessment in ARDS would require validation in a prospective clinical study.

Key Points: 
  • The clinical utility of subphenotypic assessment in ARDS would require validation in a prospective clinical study.
  • In current clinical practice, risk stratification for patients with ARDS solely depends on the PaO2/FiO2 clinical measure.
  • The retrospective analysis drew on data from six randomized clinical trials in adult patients with ARDS (five U.S. and one international study).
  • Identification of acute respiratory distress syndrome subphenotypes de novo using routine clinical data: a retrospective analysis of ARDS clinical trials.

FDA Grants the Hemolung® De Novo Clearance

Retrieved on: 
Monday, November 15, 2021
Health, FDA, Medical Devices, Other Health, General Health, Clinical Trials, Biotechnology, GMP, University, ICU, Carbon dioxide, Hypercapnia, MD, COPD, CO2, CEO, Doctor of Philosophy, Technology, Failure, Food, De novo, ECMO, The Act, ECCO2R, PCO2, COVID, COVID-19, Chronic obstructive pulmonary disease, Multimedia, Emergency Use Authorization, Food and Drug Administration Amendments Act of 2007, Respiratory failure, Mercer University Health Sciences Center, Extracorporeal, Ventilation, Philips, Hospital, Partial pressure, Company, Failure rate, Nursing, EUA, COVID 19, Physician, Louisiana, Patient, Risk, FDA, Dietary supplement, Medical device, Pharmaceutical industry

The Hemolung System is the first and only ECCO2R device cleared by the FDA.

Key Points: 
  • The Hemolung System is the first and only ECCO2R device cleared by the FDA.
  • In order to demonstrate benefit over risk, ALung submitted data to FDA from over 1,000 Hemolung patient treatments on clinical safety and over 230 Hemolung patient treatments on clinical performance outcomes.
  • This clinical data along with all of our pre-clinical data demonstrated to the FDA that the clinical benefits of the Hemolung for ECCO2R therapy has been substantiated.
  • For more information on the use of the Hemolung RAS for COVID-19 patients, please visit www.alung.com/covid-19
    *The Hemolung RAS has been authorized for the above emergency use by FDA under an EUA.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 10, 2021
Hypoxia, Cancer, Industry, Food, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Public expenditure, Partial pressure, TCOM, American Cancer Society, Exertion, Blood gas tension, ILD, Risk, Seventh Avenue station (IND lines), Efficiency, Altitude, Volunteering, Nephrology, Plasma, Tissue, Trial of the century, Research, GLOBE, Cardiology, Patient, FDA, Particular, Adult, Compliance, Private Securities Litigation Reform Act, TSC, U.S. Securities and Exchange Commission, Marginal cost, NASDAQ, CEO, Tumor hypoxia, Disease, Investigational New Drug, Neurology, VO2, Program, Diffusion Pharmaceuticals, Carbon monoxide, Blood, Annual report, Company, Oxygen, DLCO, Critical care, Pharmaceutical industry, Medical imaging

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), a biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced financial results for the third quarter of 2021 and provided a business update.

Key Points: 
  • CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), a biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced financial results for the third quarter of 2021 and provided a business update.
  • We believe this is an exciting time for Diffusion Pharmaceuticals.
  • Diffusion anticipates initiating the ILD-DLCO Trial late in the fourth quarter of 2021 and completing the trial in the first quarter of 2022, with topline results reported within two months of study completion.
  • General and administrative expenses were $1.9 million during the third quarter of 2021 versus $2.1 million in the comparable quarter last year.

Global Carbon Capture and Storage Market Report 2021-2026: Enhanced Oil Recovery Offers Strong Growth Opportunities

Retrieved on: 
Friday, October 22, 2021
Carbon, Research, Technology, Polyurethane, Growth, Carbon capture and storage, Biomass, CO2, Power, Hydrogen, Policy, EOR, Partial pressure, Food, Post-combustion capture, CAGR, COVID-19, Attention, CCS, Pet, Coal, Renewable energy

DUBLIN, Oct. 22, 2021 /PRNewswire/ -- The "Carbon Capture and Storage - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 22, 2021 /PRNewswire/ -- The "Carbon Capture and Storage - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 11.3% share of the global Carbon Capture and Storage market.
  • Carbon capture efforts are further favored by increasing focus of companies to investigate new use cases for captured carbon dioxide.
  • The 45Q tax credits for carbon oxide sequestration represent progressive CCS-specific incentive globally to promote investment in carbon capture and sequestration.